NEW YORK, June 18, 2015 /PRNewswire/ -- This report analyzes the worldwide markets for Botulinum Toxin in US$ Million by the following Segments: Cosmetic Applications, and Therapeutic Applications. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 19 companies including many key and niche players such as -
Allergan, Inc.
Ipsen Group
Medy-Tox Incorporated
Mentor Corporation
Metabiologics, Inc.
Read the full report: http://www.reportlinker.com/p0119494-summary/view-report.html
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
Cosmetic Applications I-3
Therapeutic Applications I-3
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW II-1
A Prelude II-1
Factors Propelling the BT Market - In a Nut Shell II-1
Botulinum Toxin: "The Science, The Hopes & the Risks" II-3
Developed Regions Continue to Hold Sway over Global Botulinum
Toxin Market II-4
Increasing Healthcare Spending in Emerging Markets:
Opportunities in Store II-4
Table 1: Healthcare Spending as % of GDP in Select Countries
(2011) (includes corresponding Graph/Chart) II-5
Developing Markets - Provide Huge Growth Potential II-5
India & China Offer Significant Growth Opportunities II-6
Table 2: Ten Largest Populated Countries Worldwide (July
2013): Total Population (in Millions) by Age Group 0-14
Years, 15-44 Years, 45-64 Years, and 65+ Years for China,
India, USA, Indonesia, Brazil, Pakistan, Nigeria,
Bangladesh, Russia and Japan (includes corresponding
Graph/Chart) II-7
Table 3: Ten Largest Populated Countries Worldwide (July
2013): Percentage Population by Age Group 0-14 Years, 15-44
Years, 45-64 Years, and 65+ Years for China, India, USA,
Indonesia, Brazil, Pakistan, Nigeria, Bangladesh, Russia and
Japan (includes corresponding Graph/Chart) II-8
Pharma Companies Keenly Eye Lucrative BT Market II-8
Rising Disposable Incomes Propel Sales II-8
Table 4: Annual Disposable Incomes in US$ '000 for Select
Countries (2012) (includes corresponding Graph/Chart) II-9
Societal Pressure to Look Young Peps Demand II-9
Longer Life Expectancy Bolsters Market Growth II-10
Table 5: Life Expectancy for Select Countries in Number of
Years (2013) (includes corresponding Graph/Chart) II-10
Rise in the Number of Muscoskeletal Indications - An
Opportunity Indicator II-11
2. COMPETITION II-12
Allergan Wields the Scepter II-12
Table 6: Leading Players in the Global Botulinum Toxin Market
(2013): Percentage Breakdown of Value Sales for Allergan,
Ipsen, Medy-Tox, Merz and Others (includes corresponding
Graph/Chart) II-12
Regional Presence of Available Botulinum Toxin Products II-13
Allergan's Botox Faces the Heat of Competition II-13
PurTox to Offer Competition to Botox® II-13
Revance Therapeutics: All Hopes on the Topical Botox Formulation II-13
Daewoong Pharmaceutical All Set to Make a Mark on the
International Scenario II-14
J&J's New Drug Candidate to Threaten Botox's Monopoly II-14
3. MARKET TRENDS & ISSUES II-15
Rising Demand for Non-Invasive Cosmetic Surgical Procedures to
Bode Well for BT Market II-15
Leading Non-Invasive Cosmetic Surgeries in the World (2013) II-15
Acceptance for Cosmetic BTX Treatment Grows II-15
Unmet Medical Needs Encourage Off-Label Use: A Cause for
Concern or Jubilation? II-16
Urgent Need for Physician Education about Off Label Usage II-16
High Voltage Ad Campaigns Boost Patient Awareness II-16
Digital Revolution to Impact Consumer Choices II-17
Financing of Non-Reimbursed Healthcare: The Need of the Hour II-17
Combination Therapies: A Double Whammy Success II-17
Short-lived Aesthetic Effects: A Strong Business Case for
Revision Treatments II-18
Consolidation Blows in the Aesthetic Healthcare Industry II-18
Undesirable Side Effects: A Challenge to Reckon With II-18
Immunogenicity Undermines Patient Compliance II-19
Reduction of Protein Load in BTX Products - The Probable
Answer for Immunogenicity II-19
Antigenicity: A Problematic Issue in Drug Development II-19
Stringent Regulations Delay Market Approval & Put
Reimbursements in Limbo II-20
Non-Injectable Alternatives to Turn On the Heat II-20
Alternative Methods of Botulinum Application under
Development - A Review II-21
Higher Product Costs to Challenge Market Growth II-21
Consumer Skepticism: The Biggest Challenge to Beat II-21
Animal Cruelty - A Part & Parcel of Botox Testing II-22
Botulinum Toxins - A Wonder Drug or Bio-terror Threat? II-22
Fears of Terrorism & Biological Warfare Thwart International
Trade II-23
4. PRODUCT/INDUSTRY DYNAMICS II-24
Comparison of Botox®, Dysport® and Xeomin® by Indications and
Year of Approval II-24
Scarce Differentiation Between the Four Approved BTX Products II-25
Comparison of Leading Neurotoxins - Botox, Dysport and
Xeomin by Safety and Efficacy II-26
Botox® - An Overview II-26
Key Characteristics of Botox® and Botox® Cosmetic II-27
Common Adverse Reactions with Botox II-27
Approvals and Indications of Botox in Select Regions II-28
Therapeutics to Offer Higher Prospects for Botox II-28
Botox Therapeutic Approvals in the US by Indication II-28
Migraine Indication Bolsters Allergan's Botox Sales II-29
Dysport® II-29
Key Characteristics of Dysport® II-30
Ipsen Counts on New Indications for Future Growth of Dysport II-30
Dysport Therapeutic Development Pipeline by Region II-31
Dysport Cosmetic Development Pipeline by Region II-31
Next Generation Dysport - A Breakthrough in BTX Market on the
Cards II-31
Xeomin® II-31
Key Characteristics of Xeomin® II-32
Xeomin Development Pipeline: Approved and Investigational
Indications as of 2011 II-32
Global Expansion Helps Merz Gain in the BTX Market II-32
Myobloc®/NeuroBloc® II-33
Key Characteristics of Myobloc® II-33
Myobloc - Still Long Way to Go II-33
Meditoxin® II-34
Meditoxin® Expanding Its Wings across the Globe II-34
PurTox® II-34
Key Characteristics of PurTox® II-34
PurTox Beckons Success in Clinical Trial Stage II-34
RT001 II-34
Revance's RT001 - Potential Revolution in BTX Market under
Development II-34
How Does RT001 Work? II-35
RT001 - A Potential Convenient Treatment Option for
Hyperhydrosis Patients II-35
RT002 II-35
RT002 - Opportunities in the Therapeutics Arena II-36
A Peek into the Future of RT002 Research II-36
5. PRODUCT OVERVIEW II-37
Botulinum Toxin: A Poison That Cures II-37
Structure & Mechanism of Action II-37
Disadvantages II-38
Classification of Botulinum Toxin II-38
Botulinum Toxin Type A II-38
Historical Timeline of Botulinum Toxin: 1885-2002 II-39
Botulinum Toxin Type B II-39
Procedure II-39
Anaesthesia II-39
Injection Procedure II-40
Applications of Botulinum Toxin II-40
Cosmetic Applications II-40
Glabellar Lines II-40
Facial Wrinkles II-40
Key Cosmetic Indications for Botulinum Toxin II-41
Crow's Feet II-41
Forehead Rhytids II-41
Temporal Brow Lift II-41
Lower Eyelid Rhytids II-42
Downturned Lips II-42
Pebbly Chin II-42
Therapeutic Applications II-42
Movement Disorders/Pain II-42
Cervical Dystonia II-42
Hemifacial Spasm II-42
Blepharospasm II-43
Strabismus II-43
Table 7: Site of Injection and Doses of Neurotoxins used
in the Treatment of Dystonias II-44
Chronic Pain II-45
Botox in Migraine Treatment II-45
List of Countries where Botox has been Approved for
Prophylaxis of Headache in Adults Suffering from Chronic
Migraine II-46
Table 8: Modes of Injection of Onabotulinum ToxinA for
Chronic Migraine by Dose and Muscle Injected II-46
Hyperhidrosis II-46
Bladder Dysfunctions II-46
Spasticity II-47
Other Applications: II-47
Side Effects II-48
An Overview of Side Effects of BTX Treatment II-48
Table 9: Side-Effects of BOTOX Treatment for Urinary
Incontinence Associated with Neuromuscular Disorders:
Percentage Breakdown of Major Conditions Reported Within 12
weeks of Injections during Phase III Clinical Trials
(includes corresponding Graph/Chart) II-48
Table 10: Side-Effects of BOTOX Treatment for Urinary
Incontinence Associated with Neuromuscular Disorders:
Percentage Breakdown of Major Conditions Reported Within 44
weeks of Injections during Phase III Clinical Trials
(includes corresponding Graph/Chart) II-49
6. RESEARCH BREAKTHROUGHS II-50
University of Kansas Researchers Study Botulinum ToxinA Role
in Minimally Invasive Treatment of Neurogenic Bladder (US) II-50
Researchers at Baylor College of Medicine Revealed Use of
Botox Injections for Treatment of Filamentary Keratitis (US) II-50
Researchers at Medical School of Hannover and Sanford-Burnham
Medical Research Institute Study Effect of the Hostile Human
Stomach Environment on BT (Germany) II-51
Investigators Prove Role of BTX A for Treatment of Achalasia II-51
Researchers at University of Freiburg Conduct New Studies on
Salmonella (Germany) II-52
Researchers at Monash University Use Botox to Resolve Asthma
Wrinkles (Australia) II-52
7. PRODUCT INTRODUCTIONS/APPROVALS II-53
Medy-TOX Submits Patent Application for Lyophilized Botulinum
Toxin II-53
Botox Receives Approval for Treatment of Ankle Disability in
the UK II-53
Anterios Develops AI-09 Next-Generation Injectable Botulinum
Product II-53
Ipsen Receives Health Canada Approval for Dysport® II-53
Eisai Announces Plans to Launch Nerbloc® in Japan II-53
Cangene Receives FDA Approval for Botulism Antitoxin II-53
Allergan Receives FDA Approval for BOTOX® for the Treatment of
Crow's Feet Lines in Adults II-53
Merz Pharma to Launch Xeomin for Cosmetic Applications in Canada II-54
Merz Pharmaceuticals Obtains J-Code from Centers for Medicare
and Medicaid Services for Xeomin II-54
Botox Receives Health Canada Approval for Treating Neurogenic
Bladder Condition II-54
8. RECENT INDUSTRY ACTIVITY II-55
Ipsen and Galderma Expand Partnership II-55
Allergan Completes Licensing Agreement with Medytox II-55
Valeant Acquires Medicis II-55
Ipsen Acquires Syntaxin II-55
Ipsen Enters into R&D Collaboration with Harvard Medical School II-55
Galderma Commences Clinical Trials on BT-based Muscle Relaxant II-55
Anterios Conducts Phase 2b Clinical Trials on ANT-1207
Botulinum Toxin II-55
Medy-Tox Inks Technology Transfer Agreement with Allergan II-55
Revance Therapeutics Reacquires Development and
Commercialization Rights for RT001 and RT002 from Medicis II-56
Ipsen Enters into Distribution Partnership with Galderma for
Dysport II-56
Allergan Inks Development Agreement with American Medical Systems II-56
9. FOCUS ON SELECT GLOBAL PLAYERS II-57
Allergan, Inc. (US) II-57
Ipsen Group (France) II-58
Medy-Tox Incorporated (South Korea) II-58
Mentor Corporation (US) II-58
Merz Pharma GmbH & Co. KGaA (Germany) II-59
Metabiologics, Inc. (US) II-59
Revance Therapeutics, Inc. (US) II-60
US WorldMeds (US) II-60
10. GLOBAL MARKET PERSPECTIVE II-61
Table 11: World Recent Past, Current & Future Analysis for
Botulinum Toxin by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan) and Rest of World
Markets Independently Analyzed by Annual Sales Figures in US$
Million for the Years 2013 through 2020 (includes
corresponding Graph/Chart) II-61
Table 12: World Historic Review for Botulinum Toxin by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan) and Rest of World Markets Independently
Analyzed by Annual Sales Figures in US$ Million for the Years
2006 through 2012 (includes corresponding Graph/Chart) II-62
Table 13: World 15-Year Perspective for Botulinum Toxin by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and
Rest of World Markets for the Years 2006, 2014 & 2020
(includes corresponding Graph/Chart) II-63
Table 14: World Recent Past, Current & Future Analysis for
Botulinum Toxin in Cosmetic Applications by Geographic Region -
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan)
and Rest of World Markets Independently Analyzed by Annual
Sales Figures in US$ Million for the Years 2013 through 2020
(includes corresponding Graph/Chart) II-64
Table 15: World Historic Review for Botulinum Toxin in
Cosmetic Applications by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan) and Rest of
World Markets Independently Analyzed by Annual Sales Figures
in US$ Million for the Years 2006 through 2012 (includes
corresponding Graph/Chart) II-65
Table 16: World 15-Year Perspective for Botulinum Toxin in
Cosmetic Applications by Geographic Region - Percentage
Breakdown of Dollar Sales for US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan) and Rest of World Markets for
the Years 2006, 2014 & 2020 (includes corresponding
Graph/Chart) II-66
Table 17: World Recent Past, Current & Future Analysis for
Botulinum Toxin in Therapeutic Applications by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan) and Rest of World Markets Independently Analyzed by
Annual Sales Figures in US$ Million for the Years 2013 through
2020 (includes corresponding Graph/Chart) II-67
Table 18: World Historic Review for Botulinum Toxin in
Therapeutic Applications by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan) and Rest of
World Markets Independently Analyzed by Annual Sales Figures
in US$ Million for the Years 2006 through 2012 (includes
corresponding Graph/Chart) II-68
Table 19: World 15-Year Perspective for Botulinum Toxin in
Therapeutic Applications by Geographic Region - Percentage
Breakdown of Dollar Sales for US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan) and Rest of World Markets for
the Years 2006, 2014 & 2020 (includes corresponding
Graph/Chart) II-69
III. MARKET
1. THE UNITED STATES III-1
A.Market Analysis III-1
Current and Future Scenario III-1
Cosmetic Procedures: An Overview III-1
Some Interesting Facts III-2
Table 20: Number of Cosmetic and Non-cosmetic Surgical
Procedures in the US (includes corresponding Graph/Chart) III-3
Table 21: Top 5 Non-surgical Cosmetic Procedures in the US
(2013): Ranked on the Basis of Number of Procedures
Performed (includes corresponding Graph/Chart) III-3
Table 22: Total Number of Cosmetic Procedures Performed in
the US (2013) by Category III-4
Table 23: The US Market Cost Per Botulinum Toxin Procedure
(in US$) from 2007 through 2013 (includes corresponding
Graph/Chart) III-5
Major Market Trends III-5
Botulinum Toxin Drives Growth in the Facial Aesthetics Market III-5
Table 24: Gender Distribution for Botulinum Toxin
Procedures Performed in the US for the Year 2013 (includes
corresponding Graph/Chart) III-5
Table 25: Age-wise Distribution for Botulinum Toxin
Procedures Performed in the US for the Year 2013 (includes
corresponding Graph/Chart) III-6
Aging Baby Boomers Drive Aesthetic Business III-6
Table 26: North American Aging Population by Age Group:
1975-2050 (includes corresponding Graph/Chart) III-7
Expanding Physician Base Extends Impetus to Growth III-7
Table 27: Average Physician/Surgeon Fees per Procedure in
the US (2013) III-8
Demand for Professional Help On Rise III-9
Therapeutic BTX Market - New Entrants Slow in Gaining
Market Share III-9
Botox's Therapeutic Indications (Approved and
Investigational) in the US by Year of Approval/Stage III-9
Neurogenic OAB - A Relatively Smaller Market Opportunity III-9
Idiopathic OAB Bodes Healthy Prospects for Botox III-10
Competition Heats Up in the US BTX Market III-10
Key BTX Products and Associated Fillers and Implants in
the Cosmetic Botulinum Toxin Market III-11
Table 28: Leading Brands in the US Cosmetic Neurotoxin
Treatment Market (2013): Percentage Breakdown of Value
Sales for Botox, Dysport and Others (includes
corresponding Graph/Chart) III-11
Table 29: Leading Brands in the US Therapeutic Botulinum
Toxin Market (2013): Percentage Breakdown of Value Sales
(includes corresponding Graph/Chart) III-11
Botox Therapeutic to Drive Growth in Botox Franchise III-12
Dysport Takes on Botox in the Therapeutic Space III-12
Table 30: Number of Therapeutic Procedures Conducted for
Botox and Dysport for the Years 2012 and 2013 (includes
corresponding Graph/Chart) III-13
Pricing and Promotions to Help Dysport Gain Market Share in
Cosmetic Arena III-13
Table 31: Number of Cosmetic Procedures Conducted for
Botox and Dysport for the Years 2012 and 2013 (includes
corresponding Graph/Chart) III-13
Rise in Botulinum Toxin Lawsuits - A Caution Alarm for
Doctors? III-14
Product Launches/Approvals III-14
Recent Industry Activity III-15
Key Players III-16
B.Market Analytics III-19
Table 32: US Recent Past, Current & Future Analysis for
Botulinum Toxin by Application - Cosmetic and Therapeutic
Markets Independently Analyzed by Annual Sales Figures in
US$ Million for the Years 2013 through 2020 (includes
corresponding Graph/Chart) III-19
Table 33: US Historic Review for Botulinum Toxin by
Application - Cosmetic and Therapeutic Markets Independently
Analyzed by Annual Sales Figures in US$ Million for the
Years 2006 through 2012 (includes corresponding Graph/Chart) III-20
Table 34: US 15-Year Perspective for Botulinum Toxin by
Application - Percentage Breakdown of Dollar Sales for
Cosmetic and Therapeutic Markets for the Years 2006, 2014 &
2020 (includes corresponding Graph/Chart) III-21
2. CANADA III-22
Market Analysis III-22
Table 35: Canadian Recent Past, Current & Future Analysis
for Botulinum Toxin by Application - Cosmetic and
Therapeutic Markets Independently Analyzed by Annual Sales
Figures in US$ Million for the Years 2013 through 2020
(includes corresponding Graph/Chart) III-22
Table 36: Canadian Historic Review for Botulinum Toxin by
Application - Cosmetic and Therapeutic Markets Independently
Analyzed by Annual Sales Figures in US$ Million for the
Years 2006 through 2012 (includes corresponding Graph/Chart) III-23
Table 37: Canadian 15-Year Perspective for Botulinum Toxin
by Application - Percentage Breakdown of Dollar Sales for
Cosmetic and Therapeutic Markets for the Years 2006, 2014 &
2020 (includes corresponding Graph/Chart) III-24
3. JAPAN III-25
Market Analysis III-25
Table 38: Japanese Recent Past, Current & Future Analysis
for Botulinum Toxin by Application - Cosmetic and
Therapeutic Markets Independently Analyzed by Annual Sales
Figures in US$ Million for the Years 2013 through 2020
(includes corresponding Graph/Chart) III-25
Table 39: Japanese Historic Review for Botulinum Toxin by
Application - Cosmetic and Therapeutic Markets Independently
Analyzed by Annual Sales Figures in US$ Million for the
Years 2006 through 2012 (includes corresponding Graph/Chart) III-26
Table 40: Japanese 15-Year Perspective for Botulinum Toxin
by Application - Percentage Breakdown of Dollar Sales for
Cosmetic and Therapeutic Markets for the Years 2006, 2014 &
2020 (includes corresponding Graph/Chart) III-27
4. EUROPE III-28
A.Market Analysis III-28
Current and Future Scenario III-28
European BTX Cosmetics Treatments Market - A Primer III-28
Non-Invasive Cosmetic Procedures in Europe (2013):
Countries Sorted in Decreasing Order of Number of
Procedures Conducted III-28
Botox Approvals and Indications in Select European Countries III-29
Anti-Aging Treatment on the Rise among School Gate Mothers III-29
Botox Loses Market to New Entrants in Europe III-29
Regulations for Botulinum Toxin Usage in the EU III-29
Russia Mandates Registration of BTX Drugs III-30
A Focus on Select Regional Markets III-30
The United Kingdom III-30
Cosmetic Treatment Procedures in the UK III-30
Snapshots III-31
Product Approvals III-32
Recent Industry Activity III-32
Key Players III-33
B.Market Analytics III-34
Table 41: European Recent Past, Current & Future Analysis
for Botulinum Toxin by Application - Cosmetic and
Therapeutic Markets Independently Analyzed by Annual Sales
Figures in US$ Million for the Years 2013 through 2020
(includes corresponding Graph/Chart) III-34
Table 42: European Historic Review for Botulinum Toxin by
Application - Cosmetic and Therapeutic Markets Independently
Analyzed by Annual Sales Figures in US$ Million for the
Years 2006 through 2012 (includes corresponding Graph/Chart) III-35
Table 43: European 15-Year Perspective for Botulinum Toxin
by Application - Percentage Breakdown of Dollar Sales for
Cosmetic and Therapeutic Markets for the Years 2006, 2014 &
2020 (includes corresponding Graph/Chart) III-36
5. ASIA-PACIFIC III-37
A.Market Analysis III-37
Non-Invasive Cosmetic Procedures in Asia-Pacific (2013):
Countries Sorted in Decreasing Order of Number of
Procedures Conducted III-37
Botox Approvals and Indications in Select Asian Countries III-37
A Peek into Select Markets III-38
China III-38
Chinese Facial Injectables Market to Register Robust Growth III-38
India - An Emerging Market for Botox III-38
Table 44: Cost of Select Popular Cosmetic Procedures in
India (2013) (includes corresponding Graph/Chart) III-39
South Korean BTX Market - An Overview III-39
Table 45: South Korean Botulinum Toxin Use by Application
for the Years 2005, 2011 and 2013 (includes corresponding
Graph/Chart) III-39
A List of the Domestic Botox Products in Korea (2013) III-40
Meditoxin Dominates Domestic BTX Market III-41
Table 46: Leading Players in the South Korean Botulinum
Toxin Market (2013): Percentage Breakdown of Value Sales
for Allergan, Huzel, Medy-Tox and Others (includes
corresponding Graph/Chart) III-41
Medy-Tox Threatened by Growing Popularity of Daewoong
Pharmaceutical III-41
Australia - A Well Supported Market III-41
Product Launches/Approvals III-41
Recent Industry Activity III-42
Key Player III-42
B.Market Analytics III-43
Table 47: Asia-Pacific Recent Past, Current & Future
Analysis for Botulinum Toxin by Application - Cosmetic and
Therapeutic Markets Independently Analyzed by Annual Sales
Figures in US$ Million for the Years 2013 through 2020
(includes corresponding Graph/Chart) III-43
Table 48: Asia-Pacific Historic Review for Botulinum Toxin
by Application - Cosmetic and Therapeutic Markets
Independently Analyzed by Annual Sales Figures in US$
Million for the Years 2006 through 2012 (includes
corresponding Graph/Chart) III-44
Table 49: Asia-Pacific 15-Year Perspective for Botulinum
Toxin by Application - Percentage Breakdown of Dollar Sales
for Cosmetic and Therapeutic Markets for the Years 2006,
2014 & 2020 (includes corresponding Graph/Chart) III-45
6. REST OF WORLD III-46
A.Market Analysis III-46
Current and Future Scenario III-46
Latin American Facial Injectables Market to Record Strong
Growth III-46
Cosmetic Surgery Market III-46
Health Ministry Ban on Cosmetic Botox Treatment by Dentists
(Israel) III-46
Botox Approvals and Indications in RoW III-47
Botox Approvals and Indications in Select Latin American
Regions III-47
Botox Approvals and Indications in Other Select Global Regions III-47
B.Market Analytics III-48
Table 50: Rest of World Recent Past, Current & Future
Analysis for Botulinum Toxin by Application - Cosmetic and
Therapeutic Markets Independently Analyzed by Annual Sales
Figures in US$ Million for the Years 2013 through 2020
(includes corresponding Graph/Chart) III-48
Table 51: Rest of World Historic Review for Botulinum Toxin
by Application - Cosmetic and Therapeutic Markets
Independently Analyzed by Annual Sales Figures in US$
Million for the Years 2006 through 2012 (includes
corresponding Graph/Chart) III-49
Table 52: Rest of World 15-Year Perspective for Botulinum
Toxin by Application - Percentage Breakdown of Dollar Sales
for Cosmetic and Therapeutic Markets for the Years 2006,
2014 & 2020 (includes corresponding Graph/Chart) III-50
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 19 (including Divisions/Subsidiaries - 23)
The United States (9)
Japan (2)
Europe (6)
- France (1)
- Germany (1)
- The United Kingdom (3)
- Rest of Europe (1)
Asia-Pacific (Excluding Japan) (6)
Read the full report: http://www.reportlinker.com/p0119494-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001
SOURCE Reportlinker
Share this article